168 related articles for article (PubMed ID: 33472457)
1. Delivery of toll-like receptor agonists by complement C3-targeted liposomes activates immune cells and reduces tumour growth.
Francian A; Widmer A; Olsson T; Ramirez M; Heald D; Rasic K; Adams L; Martinson H; Kullberg M
J Drug Target; 2021 Aug; 29(7):754-760. PubMed ID: 33472457
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral delivery of antigen with complement C3-bound liposomes reduces tumor growth in mice.
Francian A; Namen S; Stanley M; Mann K; Martinson H; Kullberg M
Nanomedicine; 2019 Jun; 18():326-335. PubMed ID: 30419362
[TBL] [Abstract][Full Text] [Related]
3. Enhancing T Cell and Antibody Response in Mucin-1 Transgenic Mice through Co-Delivery of Tumor-Associated Mucin-1 Antigen and TLR Agonists in C3-Liposomes.
Arabi A; Aria Soltani S; Maniaci B; Mann K; Martinson H; Kullberg M
Pharmaceutics; 2023 Dec; 15(12):. PubMed ID: 38140114
[TBL] [Abstract][Full Text] [Related]
4. Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant.
Hildebrand D; Metz-Zumaran C; Jaschkowitz G; Heeg K
Front Immunol; 2019; 10():1279. PubMed ID: 31214204
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of novel bone marrow myeloid DEC205+Gr-1+ cell subsets that differentially express chemokine and TLRs.
Lamb RJ; Capocasale RJ; Duffy KE; Sarisky RT; Mbow ML
J Immunol; 2007 Jun; 178(12):7833-9. PubMed ID: 17548621
[TBL] [Abstract][Full Text] [Related]
6. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus.
Domingues R; de Carvalho GC; da Silva Oliveira LM; Futata Taniguchi E; Zimbres JM; Aoki V; da Silva Duarte AJ; Sato MN
Br J Dermatol; 2015 Jan; 172(1):48-55. PubMed ID: 24976336
[TBL] [Abstract][Full Text] [Related]
7. TLR agonist combinations that stimulate Th type I polarizing responses from human neonates.
Surendran N; Simmons A; Pichichero ME
Innate Immun; 2018 May; 24(4):240-251. PubMed ID: 29673285
[TBL] [Abstract][Full Text] [Related]
8. Impact of in vitro costimulation with TLR2, TLR4 and TLR9 agonists and HIV-1 on antigen-presenting cell activation.
Giraldo DM; Hernandez JC; Urcuqui Inchima S
Intervirology; 2015; 58(2):122-9. PubMed ID: 25896146
[TBL] [Abstract][Full Text] [Related]
9. Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.
Francian A; Mann K; Kullberg M
Int J Nanomedicine; 2017; 12():5149-5161. PubMed ID: 28790822
[TBL] [Abstract][Full Text] [Related]
10. Expression and function of Toll-like receptors on dendritic cells and other antigen presenting cells from non-human primates.
Ketloy C; Engering A; Srichairatanakul U; Limsalakpetch A; Yongvanitchit K; Pichyangkul S; Ruxrungtham K
Vet Immunol Immunopathol; 2008 Sep; 125(1-2):18-30. PubMed ID: 18571243
[TBL] [Abstract][Full Text] [Related]
11. [Effects of different Toll-like receptor agonists on the function of T helper cells in mice].
Li X; Zhang Y; Yang B; Wu C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2015 Nov; 31(11):141-1446. PubMed ID: 26522348
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant cationic liposomes presenting MPL and IL-12 induce cell death, suppress tumor growth, and alter the cellular phenotype of tumors in a murine model of breast cancer.
Meraz IM; Savage DJ; Segura-Ibarra V; Li J; Rhudy J; Gu J; Serda RE
Mol Pharm; 2014 Oct; 11(10):3484-91. PubMed ID: 25179345
[TBL] [Abstract][Full Text] [Related]
13. Nanoparticle-delivered multimeric soluble CD40L DNA combined with Toll-Like Receptor agonists as a treatment for melanoma.
Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Langer R; Zugates GT; Anderson DG; Kornbluth RS
PLoS One; 2009 Oct; 4(10):e7334. PubMed ID: 19812695
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial delivery of antigen and TLR agonists via PLGA nanoparticles modulates Leishmania major-infected-macrophages activation.
Katebi A; Varshochian R; Riazi-Rad F; Ganjalikhani-Hakemi M; Ajdary S
Biomed Pharmacother; 2021 May; 137():111276. PubMed ID: 33485119
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
17. The differences in immunoadjuvant mechanisms of TLR3 and TLR4 agonists on the level of antigen-presenting cells during immunization with recombinant adenovirus vector.
Lebedeva E; Bagaev A; Pichugin A; Chulkina M; Lysenko A; Tutykhina I; Shmarov M; Logunov D; Naroditsky B; Ataullakhanov R
BMC Immunol; 2018 Jul; 19(1):26. PubMed ID: 30055563
[TBL] [Abstract][Full Text] [Related]
18. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
19. Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6.
Häcker H; Vabulas RM; Takeuchi O; Hoshino K; Akira S; Wagner H
J Exp Med; 2000 Aug; 192(4):595-600. PubMed ID: 10952730
[TBL] [Abstract][Full Text] [Related]
20. Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells.
Kullberg M; Martinson H; Mann K; Anchordoquy TJ
Nanomedicine; 2015 Aug; 11(6):1355-63. PubMed ID: 25839391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
